Compare Novartis AG (NVS) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Invesco Preferred ETF — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while Invesco Preferred ETF trades at $10.04 (market cap $3.64B). The key difference: Novartis AG is far larger — about 75.3× Invesco Preferred ETF's market cap, and Novartis AG pays a 3.31% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Invesco Preferred ETF for 94 Days on average.
| NVS | PGX | |
|---|---|---|
Market Cap | $274.00B | $3.64B |
Volume | 1,852,137 | 6,969,114 |
Sector | Health | — |
52-Week High | $168.62 | $11.61 |
52-Week Low | $121.80 | $9.97 |
Typical Hold Time | 82 Days | 94 Days |
Enterprise Value | $315.32B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
PGX trades at $9.97, down 0.89% with a bearish technical signal from moving averages despite oversold RSI readings. The stock shows identical support and resistance at $10, indicating consolidation. Recent dividend payments of $0.06 were declared for July and September 2026, providing income appeal. Financial ratios including P/E, P/S, and ROE are unavailable in current data, limiting fundamental visibility.
The outlook remains cautious due to bearish technical momentum and lack of current financial metrics. Income investors may find dividend payments attractive, but absence of earnings data and weak price action suggest near-term pressure. Key risks include undefined profitability and competitive challenges in the preferred ETF space highlighted by recent media coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
